CHA Biotech announced on May 21 that Kang Jae-seon, Executive Director of Clinical Operations, received a ministerial award from the Ministry of Health and Welfare during the '2026 World Clinical Trials Day' ceremony held on May 20.
World Clinical Trials Day commemorates the comparative clinical study conducted by British physician James Lind in 1747 to treat scurvy, highlighting the importance of clinical trials and honoring the contributions of researchers.
This year's ceremony, organized by the Ministry of Health and Welfare and the National Clinical Trial Support Foundation, took place at the Dongdaemun Design Plaza (DDP) in Seoul under the theme 'Collaborative Innovation for Global Clinical Trials for Better Treatments.'
Kang Jae-seon is responsible for clinical development operations at CHA Biotech, driving global commercialization efforts. He has led various domestic and international clinical trials for multiple indications at the Mokam Biotech Research Institute and GC Green Cross, guiding them through approval and product launch.
Kang stated, "Cell and gene therapies (CGT) present new possibilities for treating cancer and rare, intractable diseases. We will continue to achieve development results in areas with significant unmet medical needs, such as recurrent glioblastoma and premature ovarian failure."
Meanwhile, CHA Biotech is building its cell therapy technology and production infrastructure based on a cell library applicable to various diseases. The company currently holds over 80 related patents and is advancing the development of cell therapies targeting intractable diseases.
Recently, CHA Biotech has accelerated its collaboration for global market entry by signing a memorandum of understanding (MOU) with Yonsei University's Biohealth Technology Holding Company to foster startups in the biohealth sector.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.